The European Federation of Pharmaceutical Industries and Associations continues to have major concerns around the ongoing focus of Japan policy reforms on reducing the budgetary costs of medicines, and is calling for more inclusive and interactive discussions between the government, industry and patients to ensure timely access to innovation.
“We would like to stimulate an open and collaborative approach involving all the different stakeholders,” the group’s global president Jean-Christophe...






